Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib

PHASE2CompletedINTERVENTIONAL
Enrollment

262

Participants

Timeline

Start Date

September 12, 2012

Primary Completion Date

November 8, 2017

Study Completion Date

April 12, 2022

Conditions
Chronic Phase Chronic Myeloid Leukemia
Interventions
DRUG

Imatinib

DRUG

Dasatinib

Trial Locations (101)

0

Local Institution - 0093, La Plata

1083

Local Institution, Budapest

1221

Local Institution - 0080, Ramos Mejía

2170

Local Institution - 0099, Merksem

4000

Local Institution - 0049, San Miguel de Tucumán

4010

Local Institution - 0024, Linz

4600

Local Institution - 0022, Wels

5530

Local Institution, Yvoir

6020

Local Institution - 0026, Innsbruck

6725

Local Institution - 0104, Szeged

8036

Local Institution - 0043, Graz

8280

Local Institution, Fürstenfeld

10143

Local Institution - 0025, Orbassano

10400

Local Institution, Bangkok

12808

Local Institution - 0067, Prague

15232

Hillman Cancer Center, Pittsburgh

15706

Local Institution - 0017, A Couruna

20900

Local Institution - 0046, Monza

25123

Local Institution - 0106, Brescia

25701

Edwards Comprehensive Cancer Center, Huntington

28007

Local Institution - 0012, Madrid

35010

Local Institution - 0015, Las Palmas de Gran Canaria

37007

Local Institution - 0013, Salamanca

40002

Local Institution - 0052, Khon Kaen

40138

Local Institution, Bologna

44000

Local Institution, Nantes

45004

Local Institution - 0011, Toledo

45242

Local Institution - 0002, Cincinnati

46237

Franciscan St. Francis Health, Indianapolis

46307

Northern Indiana Cancer Research Consortium, Crown Point

50134

Local Institution - 0027, Florence

50200

Local Institution - 0055, Muang

52242

University Of Iowa, Iowa City

53226

Local Institution - 0005, Milwaukee

54511

Local Institution - 0038, Vandœuvre-lès-Nancy

55905

Local Institution - 0010, Rochester

59037

Local Institution - 0041, Lille

60208

Northwestern University, Evanston

61801

Carle Cancer Center, Urbana

69495

Local Institution, Pierre-Bénite

70124

Local Institution, Bari

77030

Michael E Debakey VAMC, Houston

78041

Institute of Oncology Hematology Biomedical Research, Laredo

78157

Local Institution - 0045, Le Chesnay

80131

Local Institution, Napoli

90033

University Of Southern California University Hospital, Los Angeles

90603

Local Institution - 0078, Whittier

92335

Local Institution - 0006, Fontana

92801

Local Institution - 0004, Anaheim

95119

Local Institution - 0112, San Jose

95124

Local Institution, Catania

95661

Local Institution - 0110, Roseville

100044

Local Institution - 0071, Beijing

100071

Local Institution - 0086, Beijing

110001

Local Institution - 0094, Shenyang

150010

Local Institution - 0084, Haerbin

200025

Local Institution - 0076, Shanghai

210029

Local Institution - 0073, Nanjing

215000

Local Institution - 0077, Suzhou

250012

Local Institution - 0101, Jinan

300020

Local Institution - 0069, Tianjin

310003

Local Institution - 0072, Hangzhou

350001

Local Institution - 0070, Fuzhou

430030

Local Institution - 0102, Wuhan

Local Institution - 0096, Wuhan

510080

Local Institution - 0082, Guangzhou

510515

Local Institution - 0074, Guangzhou

518035

Local Institution - 0103, Shenzhen

610041

Local Institution - 0075, Chengdu

710000

Local Institution - 0088, Xi'an

94589-2441

Local Institution - 0009, Vallejo

06489

Local Institution - 0089, Southington

37203-1625

Local Institution - 0001, Nashville

4102-4200

Local Institution - 0051, Buenos Aires

C1114AAN

Local Institution - 0057, Buenos Aires

CP3400

Local Institution - 0100, Corrientes

1090 Wien

Local Institution - 0023, Vienna

B-8000

Local Institution - 0065, Bruges

74605-020

Local Institution - 0083, Goiânia

80060-900

Local Institution, Curitiba

13083-970

Local Institution - 0063, Campinas

14048-900

Local Institution, Ribeirão Preto

08270-070

Local Institution - 0059, São Paulo

20211-030

Local Institution - 0062, Rio de Janeiro

20231-050

Local Institution - 0058, Rio de Janeiro

Local Institution - 0111, Rio de Janeiro

E2L 4L2

Local Institution - 0020, Saint John

625 00

Local Institution - 0032, Brno

500 05

Local Institution, Hradec Králové

775 20

Local Institution, Olomouc

100 34

Local Institution, Prague

00144

Local Institution - 0021, Roma

00161

Local Institution - 0033, Rome

30-510

Local Institution - 0048, Krakow

80-952

Local Institution - 0047, Gdansk

40-032

Local Institution - 0098, Katowice

02-776

Local Institution - 0064, Warsaw

06351

Local Institution - 0039, Seoul

137-701

Local Institution - 0050, Seoul

138-736

Local Institution - 0040, Seoul

08908

Local Institution - 0018, L'Hospitalet Del Llobregat

All Listed Sponsors
collaborator

ICON Clinical Research

INDUSTRY

collaborator

PPD Development, LP

INDUSTRY

collaborator

Molecular MD

UNKNOWN

collaborator

MultiPharma

UNKNOWN

collaborator

Q2 Solutions

INDUSTRY

collaborator

Donald E. Morisky

UNKNOWN

collaborator

MD Anderson Symptom Inventory (MDASI-CML)

UNKNOWN

collaborator

OBiS, Inc

UNKNOWN

collaborator

Steering Committee

UNKNOWN

lead

Bristol-Myers Squibb

INDUSTRY